Last Week in Longevity #5 - $ 194M raised + 13.3% CAGR forecast
Your weekly business digest of everything that happened in longevity.
đ Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.
đ¸ Closed funding rounds
US$ 194M raised across 8 deals (âď¸ +304% vs. US$ 48M across 6 deals last week)
NRG Therapeutics - US$ 68M Series B
The Stevenage-based (UK) company is trying to preserve mitochondrial health as a treatment for neurodegenerative diseases like ALS or Parkinsonâs disease. Their small molecule inhibitors target the mitochondrial permeability transition pore (mPTP), a mechanism associated with cell death and neuroinflammation. Investors include, among others British Business Bank, SV Health Investorsâ Dementia Discovery Fund (DDF), M Ventures, Novartis Venture Fund, and Criteria Bio Ventures. Learn more here: Company | Article
Epigenic Therapeutics - US$ 60M Series B
The 4-year-old Shanghai-based (CN) company is developing a way to turn off disease-related genes, not by cutting or editing DNA, but by using âepigenetic switchesâ. They are currently targeting high cholesterol (LDL) and a cure for chronic hepatitis B. The investment was led by Lapam Capital with support from current backers OrbiMed and Qiming Venture Partners. Learn more here: Company | Article
Congruence Therapeutics - US$ 32M
The 4-year-old Montreal-based (CA) drug development company is creating small molecules that act as repair kits for defective proteins, restoring their natural function. The funding round comes on the heels of advancing its genetic obesity drug into a Phase Ib clinical trial. Investors include, among others FSTQ, Amplitude Ventures, Lumira, BDC Capitalâs Thrive Venture Fund, Investissement Quebec, OrbiMed, Silver Arc. Learn more here: Company | Article
Revalia Bio - US$ 14.5M Seed
The 2-year-old New Haven-based (US) company helps drug developers to test new therapies on real human organs in pre-clinical research. The organs used in the trials have been revived and sustained using proprietary perfusion technology and come from donors whose organs are not viable for transplant. Investors include Americaâs Frontier Fund, Sierra Ventures, and previous investors. Learn more here: Company | Article
Integra Therapeutics - US$ 12.6M Pre-Series A
The 5-year-old Barcelona-based (ES) company is developing a more precise gene writing technology (compared to CRISPR). The goal is to cure genetic, oncological and autoimmune diseases. Investors include EIC Fund (the venture arm of the European Innovation Council), Spainâs CDTI Innvierte, AdBio, Columbus, Invivo, and Takeda Ventures. Learn more here: Company | Article
NewDays - US$ 7M Seed
The 1-year-old Seattle-based (US) company launched Sunny, an AI companion that chats with people experiencing mild cognitive impairment and dementia to stimulate their mind - backed by strong clinical science and coupled with human clinician monitoring. The round was led by General Catalyst and Madrona. Learn more here: Company | Article
Minovia Therapeutics - US$ 350k Grant
The 13-year-old Haifa-based (IL) company is developing mitochondrial blood-based biomarkers that quantify mitochondrial content, quality, and function, to establish a standardised âMitoScoreâ. The research grant is sponsored by Countdown For A Cure, a foundation dedicated to accelerating mitochondrial research and medicine. Learn more here: Company | Article
Longevity.Technology - undisclosed amount
The 6-year-old London-based (UK) media company is running a longevity-focused news and data platform. The investment was led by Seveno Capital. Learn more here: Company | Article
đ¤ Exits
Thrive acquires Bionic Health for an undisclosed amount
Started out as an âAI health clinicâ in 2022, Bionic Health was acquired by Thrive, a telehealth company focused on medical weight loss and testosterone replacement therapy. Learn more here: Article
Want the full weekly funding database + exclusive analysis? Subscribe for free!
đ° Top longevity business news
Xi and Putin living forever?
At a Beijing military parade, Presidents Xi Jinping and Vladimir Putin were overheard discussing organ transplantation, biotechnology, and even the prospect of living to 150 - framing extended lifespan as a realistic future. The exchange, captured via hot mic, offers a rare glimpse into how two long-tenured leaders think about pushing biological limits. Read more here.
đ Why itâs important:
While not traditional business news, top-level political interest can accelerate longevityâs move into the mainstream. If Russia and China choose to pour money into âimmortality for autocrats,â longevity research could see a wave of new state-backed investment.Longevity Therapy Market forecast: 13.3% CAGR
The global Longevity Therapy Market was valued at USD 19.4 billion in 2023, and is projected to grow to USD 59.7 billion by 2033. Read more here.đ Why itâs important:
Another market forecast in line with everyoneâs gut feeling: How can slowing aging (and eventually reversing, as optimists would say) NOT be big business? What is striking is that the market size differs significantly from e.g. the UBS report forecasting for the Longevity Economy of USD 8tr by 2030 (up from USD 5.3tr in 2023). While I havenât compared the methodologies, the trajectory signals an imminent transition from niche research into a mainstream market with serious demand from healthcare systems, insurers, governments, and investors looking to extend healthspan at scale.The Food Supplement Market forecast: 8.4% CAGR
The supplement market reached US$ 173 billion in 2022 and is projected to reach US$ 345 billion by 2031, with a robust CAGR of 8.4% from 2024 to 2031.
đ Why itâs important:
Unlike many other parts of longevity protocols (be it gene therapies or just daily exercise), supplements are accessible, easy (no effort, just take a pill), cheap, and unregulated enough to hit the market fast. They serve as the entry point for consumers into the longevity ecosystem (e.g., collagen, NMN, spermidine, creatine). Growth to US$ 345B by 2031 validates that consumers are actively investing in preventive health and aging well.Anti-aging claims outpacing science
With clinics, supplements, and longevity interventions flooding the market promising to slow, halt, or even reverse aging, it is hard to tell which claims are evidence-based and which are marketing hype. Regulation regarding health claims exists, but it usually lags behind trends, making it essential for consumers to approach efficacy statements with caution. Read more here.đ Why itâs important:
In longevity, trust is everything - especially if the desired effect can not immediately be seen/felt by consumers. Overpromising may grab quick attention, but it risks long-term reputational damage. Sustainable growth depends on realistic messaging based on trusted data (while standardized, reliable aging biomarkers are still emerging). Nevertheless, I understand the temptation of simple, bold messaging to cut through the noise directly to the consumerâs heartâŚ
đ Events & meetups (Europe-only)
(IT) 2nd Seno-Therapeutics Summit (Sep 16-19, 2025)
(LV) 3rd International Baltic Conference on Healthy Longevity (Sep 16-17, 2025)
(CH) St. Moritz Longevity Forum (Sep 18-21, 2025)
(CH) Longevity Investors Conference (Sep 22-25, 2025)
(UK) Healf Experience (Oct 3-5, 2025)
(CH) Biostasis 2025 (Oct 10-12, 2025)
(LU) Longevity & Biohacking Retreat (Oct-Nov 24-04, 2025)
(CH) Global Longevity Summit (Oct 28-30, 2025)
(ES) 4th Longevity World Forum (Feb 18-20, 2026)
(CH) SIP Longevity Retreat (Apr 20-24, 2026)
(PT) 4th Global Longevity Med Summit (May 6-7, 2026)
(DE) LIFE Summit (May 29-30, 2026)
(IE) Longevity Summit Dublin (Jun 24-26, 2026)
(NL) HLTH Europe (Jun 15-18, 2026)
(CZ) 8th World Aging & Rejuvenation Conference (Jun 18-19, 2026)
(AT) 2nd World Congress on Future of Aging & Rejuvenation Science (Jul 20-21, 2026)
(DE) POLLY Longevity Festival (Aug 21-23, 2026)
đź Longevity jobs (Europe-only)
Germany:
(Berlin) Co-Founder / CXO @ Life Summit
(Berlin) Product Development Manager Longevity @ Sunday Naturals
(Berlin) Founder Associate @ Kalia Lab
(Berlin) Working Student Data Science @ YEARS
(MĂźnchen) Creative Designer- Video & Performance Design @ MoleQlar
(MĂźnchen) Heilpraktiker @ Longevity Mitosphere Spa
(Dßsseldorf) Ernährungscoach @ Intumind
(Karlsruhe) Medizinische Fachangestellte fĂźr Longevity-Medizin @ belleaesthetics
(Bensheim) Medizinische Fachangestellte Schwerpunkt Longevity @ Caremed²
(Rostock) Postdoc: Bioinformatics and AI for Longevity @ Uni Rostock
Rest of Europe:
(London) Product Manager @ Juniper UK
Keep building the future of longevity - one week at a time.
Fabian
P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.